ReviewBiomaterials translational2026
Empowering of novel anti-tumor formulations with quinone-based active natural products.
Review in Biomaterials translational, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of death worldwide, representing a significant threat to human health. Consequently, there is an urgent need to develop effective treatment strategies with low toxicity. Quinone-based natural products have garnered considerable attention in the field of anticancer research due to their distinctive chemical structures. These compounds play a crucial role in treating various cancers and in overcoming chemotherapy resistance through several mechanisms, including the inhibition of cell proliferation and migration, as well as the modulation of multiple signaling pathways. However, their clinical application is limited by severe side effects, which arise from certain physicochemical properties, such as poor water solubility and low biocompatibility. The advent of nanotechnology has led to the development of nanomedicine delivery systems, offering a groundbreaking approach to overcome these limitations. Nanocarriers, characterized by their excellent biocompatibility, favorable pharmacokinetics, and high drug-loading capacities, enhance the bioavailability and targeting of natural products while reducing adverse effects. Therefore, integrating quinone-based natural products with nanocarrier delivery systems has proven to be an effective anticancer strategy. This approach not only improves the absorption of drugs with poor bioavailability but also significantly reduces side effects. Various nanodelivery systems, including micelles, liposomes, inorganic nanoparticles, and biomimetic nanocarriers, are particularly effective in delivering quinone-based natural products due to their unique physical and chemical properties, thereby enhancing their solubility and stability. In addition, targeted modifications, intelligent controlled release, and combination therapy strategies have significantly improved their bioavailability and antitumor efficacy. This review systematically examines the antitumor potential of quinone-based natural products and provides a comprehensive overview of the current research and clinical application prospects of their nanodelivery systems in cancer treatment. It aims to summarize the current progress and clinical prospects of integrating these compounds with nanocarrier-based drug delivery systems in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.